July 29 Merck & Co reported
better-than-expected quarterly results, with sales of newer
drugs mostly offsetting declining sales of drugs facing generic
The No. 2 U.S. drugmaker on Tuesday said it earned $2.03
billion, or 68 cents per share, in the second quarter. That
compared with $906 million, or 30 cents per share, in the
year-earlier period, when Merck took charges for acquisitions
Excluding special items, Merck earned 85 cents per share.
Analysts, on average, were expecting 81 cents per share,
according to Thomson Reuters I/B/E/S.
(Reporting by Ransdell Pierson)